Longitudinal Changes in the European League Against Rheumatism Sjögren's Syndrome Patient Reported Index in Real-Life Practice
10.4078/jrd.2019.26.3.191
- Author:
Ji Hyoun KIM
1
;
You Jung HA
;
Eun Ha KANG
;
Yeong Wook SONG
;
Yun Jong LEE
Author Information
1. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
- Publication Type:Original Article
- Keywords:
Sjögren's syndrome;
Patient outcome assessment;
Quality of life;
Xerostomia;
Xerophthalmia
- MeSH:
Depression;
Diagnosis;
Glucocorticoids;
Humans;
Immunoglobulin G;
Patient Outcome Assessment;
Pilocarpine;
Quality of Life;
Rheumatic Diseases;
Visual Analog Scale;
Xerophthalmia;
Xerostomia
- From:Journal of Rheumatic Diseases
2019;26(3):191-199
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To investigate longitudinal changes in the European League Against Rheumatism (EULAR) Sjögren's syndrome patient reported index (ESSPRI) and to study the clinical features associated with favorable ESSPRI changes in primary Sjögren's syndrome (pSS). METHODS: At baseline and after a median period of 6.6 years, 41 pSS patients were evaluated using the ESSPRI, EULAR Sjögren's syndrome disease activity index (ESSDAI), short-form 36, xerostomia inventory (XI), and visual analog scale (VAS) scores for symptoms. The favorable subgroup included patients who were stable or showed improved to satisfactory symptom status (ESSPRI<5) and the unfavorable subgroup included those with stable or worsening to an unsatisfactory symptom status (ESSPRI ≥5). RESULTS: Median ESSPRI increased from 4.11 to 5.33 (p<0.05), although XI scores (p=0.01) and oral dryness (p<0.05) were significantly decreased. Serum immunoglobulin G level was significantly reduced (p<0.001) but ESSDAI scores were unchanged. Six (14.6%) patients showed clinical improvement in ESSDAI, and 11 (26.8%) showed improvement in ESSPRI. On comparing the favorable (n=17) and unfavorable (n=24) subgroups, the former exhibited significantly lower VAS scores for sicca and depression and XI and ESSPRI scores at baseline (all p<0.05) and more lacrimal flow (p<0.05). The favorable subgroup received a significantly lower cumulative dose of pilocarpine and glucocorticoids (both p<0.05). CONCLUSION: About 25% of pSS patients showed clinically significant ESSPRI improvement and about 40% showed a favorable ESSPRI course. Because the favorable subgroup had more lacrimal flow and less sicca symptoms at baseline, long-term patient-derived outcomes could depend on residual exocrine function at pSS diagnosis.
